Ganglioside GM3 Is Antiangiogenic in Malignant Brain Cancer

Abstract EN

Progression of malignant brain tumors is dependent upon vascularity and is associated with altered ganglioside composition and distribution.

Evidence is reviewed showing that the simple monosialoganglioside, GM3, possesses powerful antiangiogenic action against the highly vascularized CT-2A mouse astrocytoma, which primarily expresses complex gangliosides.

Brain tumors expressing high levels of GM3 are generally less vascularized and grow slower than tumors that express low levels of GM3.

GM3 inhibits angiogenesis through autocrine and paracrine effects on vascular endothelial growth factor (VEGF) and associated receptors.

GM3 should be a clinically useful compound for managing brain tumor angiogenesis.